Outlook 2021: Medtechs Must Look To Late 2021 And 2022 For A Return To Normal Times
Medtech is as attractive as it has ever been says Jefferies Healthcare
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
You may also be interested in...
The COVID-19 pandemic has fundamentally changed health care and the life sciences, KPMG analyst Kristin Pothier concludes in a new report on the medtech investment outlook.
The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.
Three central European industry associations have agreed to develop joint initiatives and form a collective voice with which to lobby decision-makers on medtech themes of mutual interest.